Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029636 | 0.90 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL4340897 | 0.87 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL6028550 | 0.86 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL4333423 | 0.84 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL6028804 | 0.84 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6028660 | 0.83 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL27556137 | 0.82 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL6028037 | 0.82 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11PTGS2 | |
| SCHEMBL6028771 | 0.79 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL27556143 | 0.78 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | claimed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| CN-1281604-C | Substituted pyrazole compounds | TEIKOKU HORMONE MFG CO LTD (JP) | 2006-10-25 | — | — | CN | disclosed |
| US-7087624-B2 | Substituted pyrazole compounds | TEIKOJU HORMONE MFG. CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1188754-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | TEIKOKU HORMONE MFG CO LTD (JP) | 2005-06-01 | — | — | EP | disclosed |
| CN-1560051-A | Substituted pyrazole compounds | �۹���ҩ��ʽ���� | 2005-01-05 | — | — | CN | disclosed |
| CN-1178931-C | Substituted pyrazole compounds | �۹���ҩ��ʽ���� | 2004-12-08 | — | — | CN | disclosed |
| US-20040087628-A1 | Substituted pyrazole compounds | MINAMI NOBUYOSHI (JP) | 2004-05-06 | — | — | US | disclosed |
| US-6667325-B1 | P38MAP kinase inhibiters; tumor necrosis factor alpha, interleukin 1 and 6 and cyclooxygenase II related diseases | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| CN-1353704-A | Substituted pyrazole compounds | TEIKOKU HORMONE MFG CO LTD (JP) | 2002-06-12 | — | — | CN | disclosed |
| EP-1188754-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087628-A1 | Substituted pyrazole compounds | CNKSR1, MAPK1, IRAK1 | MAPK14 64/4885MAPK13 79/4885MAPK12 164/4885 |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | MAPK6, SLC10A2, MAP3K6 | MAPK14 13/4885MAPK13 36/4885MAPK12 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.